IN2014KN02672A - - Google Patents
Info
- Publication number
- IN2014KN02672A IN2014KN02672A IN2672KON2014A IN2014KN02672A IN 2014KN02672 A IN2014KN02672 A IN 2014KN02672A IN 2672KON2014 A IN2672KON2014 A IN 2672KON2014A IN 2014KN02672 A IN2014KN02672 A IN 2014KN02672A
- Authority
- IN
- India
- Prior art keywords
- mammal
- csf
- ependymal cells
- apoe
- protective
- Prior art date
Links
- 102000013918 Apolipoproteins E Human genes 0.000 abstract 3
- 108010025628 Apolipoproteins E Proteins 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 abstract 3
- 102000001708 Protein Isoforms Human genes 0.000 abstract 2
- 108010029485 Protein Isoforms Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000001681 protective effect Effects 0.000 abstract 2
- 108090000565 Capsid Proteins Proteins 0.000 abstract 1
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 1
- 241000283984 Rodentia Species 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648801P | 2012-05-18 | 2012-05-18 | |
| PCT/US2013/031725 WO2013172964A1 (en) | 2012-05-18 | 2013-03-14 | Methods and compositions for treating amyloid deposits |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014KN02672A true IN2014KN02672A (https=) | 2015-05-08 |
Family
ID=49584137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2672KON2014 IN2014KN02672A (https=) | 2012-05-18 | 2013-03-14 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150183850A1 (https=) |
| EP (1) | EP2850195B1 (https=) |
| JP (2) | JP6469000B2 (https=) |
| CN (2) | CN104540952A (https=) |
| AU (1) | AU2013263346B2 (https=) |
| BR (1) | BR112014028666B1 (https=) |
| CA (1) | CA2873890C (https=) |
| ES (1) | ES2786078T3 (https=) |
| HK (1) | HK1207109A1 (https=) |
| IN (1) | IN2014KN02672A (https=) |
| RU (1) | RU2673484C2 (https=) |
| WO (1) | WO2013172964A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230145206A (ko) | 2014-11-14 | 2023-10-17 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| WO2016196507A1 (en) | 2015-05-29 | 2016-12-08 | University Of Iowa Research Foundation | Methods of delivery of transgenes for treating brain diseases |
| US20180161395A1 (en) * | 2015-06-12 | 2018-06-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical composition for the treatment of alzheimer's disease |
| CN109072274A (zh) * | 2016-04-14 | 2018-12-21 | 道健康生活医药株式会社 | 淀粉样蛋白球体（aspd）样结构体及医药组合物 |
| KR20240056729A (ko) | 2016-05-18 | 2024-04-30 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| AU2017306558B2 (en) * | 2016-08-03 | 2024-09-19 | University Of South Florida | Reelin compositions for treatment of neurological disorders |
| JP7610923B2 (ja) * | 2016-09-02 | 2025-01-09 | スパーク セラピューティクス インコーポレイテッド | Ｃｎｓ障害を治療するための方法及びベクター |
| EP3309550A1 (en) * | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Method for the detection of apolipoprotein e4 |
| CN112501208A (zh) | 2017-10-03 | 2021-03-16 | 普利维尔治疗公司 | 用于溶酶体障碍的基因疗法 |
| BR112020006661A2 (pt) | 2017-10-03 | 2020-10-13 | Prevail Therapeutics, Inc. | terapias de genes para distúrbios lipossomais |
| JP7616995B2 (ja) * | 2018-11-28 | 2025-01-17 | プリベイル セラピューティクス，インコーポレーテッド | 神経変性疾患のための遺伝子治療 |
| JP2023500793A (ja) * | 2019-10-16 | 2023-01-11 | コーネル・ユニバーシティー | アルツハイマー病に対する遺伝子治療方法 |
| EP4065600A1 (en) | 2019-11-25 | 2022-10-05 | Cornell University | Apoe gene therapy |
| BR112022019864A2 (pt) * | 2020-03-31 | 2022-11-16 | Nuo Beta Pharmaceutical Tech Shanghai Co Ltd | Composto de oxofenilarsina deuterada e uso do mesmo |
| KR20230112672A (ko) * | 2020-11-25 | 2023-07-27 | 프리베일 테라퓨틱스, 인크. | 신경변성 질환을 위한 유전자 요법 |
| WO2023108507A1 (en) * | 2021-12-15 | 2023-06-22 | National Institute Of Biological Sciences, Beijing | Recombinant aav vectors and use thereof |
| CN116063405B (zh) * | 2022-09-27 | 2025-08-29 | 广州译码基因科技有限公司 | 可提高AAV病毒包装能力的衣壳蛋白突变体MutC及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5589154A (en) * | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
| US6436996B1 (en) * | 1997-09-30 | 2002-08-20 | Duke University | Modulation of nitric oxide production |
| US6468524B1 (en) * | 2000-03-22 | 2002-10-22 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | AAV4 vector and uses thereof |
| US6855314B1 (en) | 2000-03-22 | 2005-02-15 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector for transducing brain cells and lung cells |
| GB0322645D0 (en) * | 2003-09-26 | 2003-10-29 | Melacure Therapeutics Ab | Use of antisecretory factor peptides |
| JP5136766B2 (ja) * | 2004-12-15 | 2013-02-06 | ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | キメラベクター |
| CA2606490C (en) * | 2005-05-02 | 2018-02-06 | Genzyme Corporation | Gene therapy for spinal cord disorders |
| CN102886052B (zh) * | 2006-09-14 | 2014-07-30 | 迈德詹尼克斯医疗以色列有限公司 | 长效药物制剂 |
| EP2154969B1 (en) * | 2007-05-16 | 2015-11-18 | The Brigham and Women's Hospital, Inc. | Treatment of synucleinopathies |
| EP3444346B1 (en) * | 2010-04-23 | 2022-07-27 | University of Massachusetts | Aav-based treatment of cholesterol-related disorders |
-
2013
- 2013-03-14 CN CN201380038140.1A patent/CN104540952A/zh active Pending
- 2013-03-14 US US14/402,064 patent/US20150183850A1/en not_active Abandoned
- 2013-03-14 JP JP2015512644A patent/JP6469000B2/ja active Active
- 2013-03-14 IN IN2672KON2014 patent/IN2014KN02672A/en unknown
- 2013-03-14 AU AU2013263346A patent/AU2013263346B2/en active Active
- 2013-03-14 EP EP13790429.8A patent/EP2850195B1/en active Active
- 2013-03-14 CA CA2873890A patent/CA2873890C/en active Active
- 2013-03-14 RU RU2014151218A patent/RU2673484C2/ru active
- 2013-03-14 ES ES13790429T patent/ES2786078T3/es active Active
- 2013-03-14 BR BR112014028666-3A patent/BR112014028666B1/pt active IP Right Grant
- 2013-03-14 HK HK15107526.1A patent/HK1207109A1/xx unknown
- 2013-03-14 WO PCT/US2013/031725 patent/WO2013172964A1/en not_active Ceased
- 2013-03-14 CN CN202011133829.0A patent/CN112574964A/zh active Pending
-
2018
- 2018-11-02 JP JP2018207331A patent/JP2019031564A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2873890C (en) | 2022-12-06 |
| RU2673484C2 (ru) | 2018-11-27 |
| CN104540952A (zh) | 2015-04-22 |
| CN112574964A (zh) | 2021-03-30 |
| EP2850195B1 (en) | 2020-01-22 |
| US20150183850A1 (en) | 2015-07-02 |
| HK1207109A1 (en) | 2016-01-22 |
| RU2014151218A (ru) | 2016-07-10 |
| AU2013263346A1 (en) | 2014-12-04 |
| JP6469000B2 (ja) | 2019-02-13 |
| EP2850195A4 (en) | 2015-12-09 |
| BR112014028666A2 (pt) | 2017-06-27 |
| AU2013263346B2 (en) | 2018-08-23 |
| BR112014028666B1 (pt) | 2021-12-07 |
| JP2019031564A (ja) | 2019-02-28 |
| EP2850195A1 (en) | 2015-03-25 |
| ES2786078T3 (es) | 2020-10-08 |
| WO2013172964A1 (en) | 2013-11-21 |
| CA2873890A1 (en) | 2013-11-21 |
| JP2015520161A (ja) | 2015-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014KN02672A (https=) | ||
| CA2832151C (en) | Methods and compositions for treating brain diseases | |
| MX2023007728A (es) | Composiciones para el tratamiento de esclerosis lateral amiotrofica (ela). | |
| MX2015011951A (es) | Proteinas de fusion que comprenden partes de union a pdgf y vegf y metodos de uso de las mismas. | |
| WO2015013148A3 (en) | Methods and compositions for treating brain diseases | |
| PH12017501436A1 (en) | Enhanced delivery of viral particles to the striatum and cortex | |
| MX337984B (es) | Variantes de alfa amilasa y polinucleotidos que codifican la misma. | |
| WO2015109124A3 (en) | Immunomodulatory agents | |
| PH12018501055A1 (en) | Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders | |
| MX2015014423A (es) | Administración efectiva de genes grandes por vectores aav duales. | |
| EP4219727A3 (en) | Products and methods for treatment of amyotrophic lateral sclerosis | |
| MX2017014125A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
| TN2014000438A1 (en) | Anti-fcrn antibodies | |
| MX2014004292A (es) | Variantes de glucoamilasas y polinucleotidos que las codifican. | |
| MX2015016814A (es) | Anticuerpo anti-tweakr y sus usos. | |
| MX2014002415A (es) | Variantes de glucoamilasas y polinucleotidos que las codifican. | |
| MX2014015002A (es) | Polipeptidos que tienen actividad de transgalactosilacion. | |
| MX2014004539A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
| WO2014144486A3 (en) | Vectors comprising stuffer/filler polynucleotide sequences and methods of use | |
| WO2014058866A3 (en) | Treatment of amyotrophic lateral sclerosis | |
| Dubsky et al. | Category O for the Schrödinger algebra | |
| MX2019005266A (es) | Composiciones, metodos y usos de transferencia genetica para tratar enfermedades neurodegenerativas. | |
| MX2021013104A (es) | Variantes de lipasa y polinucleotidos que las codifican. | |
| WO2013119302A3 (en) | Gh61 polypeptide variants and polynucleotides encoding same | |
| WO2014195356A3 (en) | Alpha-amylase variants and polynucleotides encoding same |